JPWO2022064428A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022064428A5 JPWO2022064428A5 JP2023518205A JP2023518205A JPWO2022064428A5 JP WO2022064428 A5 JPWO2022064428 A5 JP WO2022064428A5 JP 2023518205 A JP2023518205 A JP 2023518205A JP 2023518205 A JP2023518205 A JP 2023518205A JP WO2022064428 A5 JPWO2022064428 A5 JP WO2022064428A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- cells
- disrupted
- population
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 43
- 108090000623 proteins and genes Proteins 0.000 claims 28
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims 19
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 18
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 102100023882 Endoribonuclease ZC3H12A Human genes 0.000 claims 6
- 101710112715 Endoribonuclease ZC3H12A Proteins 0.000 claims 6
- 108020005004 Guide RNA Proteins 0.000 claims 6
- 101710191487 T cell receptor alpha chain constant Proteins 0.000 claims 6
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 claims 6
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 6
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 102100025221 CD70 antigen Human genes 0.000 claims 4
- 238000010453 CRISPR/Cas method Methods 0.000 claims 4
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 4
- 238000010362 genome editing Methods 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 101150046201 reg1 gene Proteins 0.000 claims 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- 101150088890 CD70 gene Proteins 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 101150010487 are gene Proteins 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004986 primary T-cell Anatomy 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082357P | 2020-09-23 | 2020-09-23 | |
| US63/082,357 | 2020-09-23 | ||
| US202063124429P | 2020-12-11 | 2020-12-11 | |
| US63/124,429 | 2020-12-11 | ||
| US202163225673P | 2021-07-26 | 2021-07-26 | |
| US63/225,673 | 2021-07-26 | ||
| PCT/IB2021/058704 WO2022064428A1 (en) | 2020-09-23 | 2021-09-23 | Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542348A JP2023542348A (ja) | 2023-10-06 |
| JPWO2022064428A5 true JPWO2022064428A5 (https=) | 2024-09-24 |
| JP2023542348A5 JP2023542348A5 (https=) | 2024-09-24 |
Family
ID=78080385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518205A Pending JP2023542348A (ja) | 2020-09-23 | 2021-09-23 | Ｒｅｇｎａｓｅ－１及び／又はＴＧＦＢＲＩＩを破壊した遺伝子操作されたＴ細胞は機能性及び持続性を改善させた |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US20220090012A1 (https=) |
| EP (2) | EP4176048B1 (https=) |
| JP (1) | JP2023542348A (https=) |
| KR (1) | KR20230074515A (https=) |
| CN (1) | CN116322716A (https=) |
| AU (1) | AU2021347907A1 (https=) |
| CA (1) | CA3192280A1 (https=) |
| ES (1) | ES2993268T3 (https=) |
| IL (1) | IL301012A (https=) |
| MX (1) | MX2023003365A (https=) |
| TW (1) | TW202229545A (https=) |
| WO (1) | WO2022064428A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021009357A (es) * | 2019-02-04 | 2021-11-17 | Ksq Therapeutics Inc | Dianas de genes de combinacion para mejorar la inmunoterapia. |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2021252804A1 (en) | 2020-06-12 | 2021-12-16 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| WO2023007373A1 (en) * | 2021-07-26 | 2023-02-02 | Crispr Therapeutics Ag | Methods for manufacturing genetically engineered car-t cells |
| WO2023084399A1 (en) | 2021-11-09 | 2023-05-19 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7 |
| WO2023111913A1 (en) | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
| WO2023119201A2 (en) | 2021-12-22 | 2023-06-29 | Crispr Therapeutics Ag | Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof |
| WO2023180968A1 (en) | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof |
| WO2023180967A1 (en) | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption |
| CN119451992A (zh) | 2022-06-29 | 2025-02-14 | 克里斯珀医疗股份公司 | 靶向gpc-3的嵌合抗原受体和表达其的免疫细胞用于治疗用途 |
| WO2024023801A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene |
| WO2024023802A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene |
| WO2024023804A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene |
| WO2024059757A2 (en) * | 2022-09-14 | 2024-03-21 | Ohio State Innovation Foundation | Methods for reprograming exhausted t cells and boosting immune checkpoint blockade therapy for cancer |
| WO2024062388A2 (en) | 2022-09-20 | 2024-03-28 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20 |
| US20240115703A1 (en) * | 2022-10-10 | 2024-04-11 | Crispr Therapeutics Ag | Genetically engineered anti-cd19 car-t cells for use in treating b-cell malignancies |
| WO2024229098A2 (en) * | 2023-05-01 | 2024-11-07 | Wisconsin Alumni Research Foundation | Methods and systems for predicting potent t cell products |
| US12500832B2 (en) | 2023-08-28 | 2025-12-16 | Ciena Corporation | Establishing and advertising co-routed bidirectional paths across multiple domains |
| WO2025126049A2 (en) | 2023-12-11 | 2025-06-19 | Crispr Therapeutics Ag | Multiplex gene editing |
| WO2025137439A2 (en) * | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Engineered t cells |
| CN117844811A (zh) * | 2024-03-08 | 2024-04-09 | 上海恒润达生生物科技股份有限公司 | 靶向敲除CD70基因的sgRNA组合物及其应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| WO2010098429A1 (ja) | 2009-02-27 | 2010-09-02 | 国立大学法人大阪大学 | 免疫アジュバント組成物、及びその利用 |
| HUE041436T2 (hu) | 2009-12-10 | 2019-05-28 | Univ Minnesota | Tal-effektor-közvetített DNS-módosítás |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CA2868391A1 (en) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
| WO2014153114A1 (en) | 2013-03-14 | 2014-09-25 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| US20180112198A1 (en) | 2015-04-15 | 2018-04-26 | Saint Louis University | Tumor suppression by mcpip1 |
| JP2017002928A (ja) | 2015-06-05 | 2017-01-05 | 株式会社デンソー | 複数軸駆動用アクチュエータ |
| JP6983066B2 (ja) | 2015-06-30 | 2021-12-17 | 忠三 岸本 | 新規な肺疾患治療剤および／またはそのスクリーニング方法 |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| AU2016369490C1 (en) * | 2015-12-18 | 2021-12-23 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| BR112020008478A2 (pt) * | 2017-11-01 | 2020-10-20 | Editas Medicine, Inc. | métodos, composições e componentes para edição de crispr-cas9 de tgfbr2 em células t para imunota-rapia |
| US20190284553A1 (en) * | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| KR20200130826A (ko) | 2018-03-15 | 2020-11-20 | 케이에스큐 세러퓨틱스 인코포레이티드 | 개선된 면역요법을 위한 유전자-조절 조성물 및 방법 |
| US12227763B2 (en) | 2018-05-11 | 2025-02-18 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| EP3804759A4 (en) | 2018-06-06 | 2022-07-20 | Osaka University | METHODS OF TREATMENT OF DANDRUFF OR PREVENTION OF GNASE 1 SECONDARY DISEASES |
| WO2020032160A1 (ja) | 2018-08-09 | 2020-02-13 | 国立大学法人大阪大学 | 炎症性腸疾患治療薬およびそのスクリーニング方法 |
| CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| SG11202103832SA (en) | 2018-11-07 | 2021-05-28 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
| US20220133790A1 (en) * | 2019-01-16 | 2022-05-05 | Beam Therapeutics Inc. | Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance |
| US20220249558A1 (en) * | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| JP6957572B2 (ja) | 2019-09-19 | 2021-11-02 | フランスベッド株式会社 | ベッド装置 |
| TW202132333A (zh) * | 2019-11-13 | 2021-09-01 | 瑞士商Ｃｒｉｓｐｒ治療公司 | 製造可表達嵌合抗原受體的ｔ細胞製法 |
-
2021
- 2021-09-23 CN CN202180062948.8A patent/CN116322716A/zh active Pending
- 2021-09-23 IL IL301012A patent/IL301012A/en unknown
- 2021-09-23 EP EP21787042.7A patent/EP4176048B1/en active Active
- 2021-09-23 ES ES21787042T patent/ES2993268T3/es active Active
- 2021-09-23 TW TW110135390A patent/TW202229545A/zh unknown
- 2021-09-23 JP JP2023518205A patent/JP2023542348A/ja active Pending
- 2021-09-23 CA CA3192280A patent/CA3192280A1/en active Pending
- 2021-09-23 EP EP24162548.2A patent/EP4397321A3/en active Pending
- 2021-09-23 WO PCT/IB2021/058704 patent/WO2022064428A1/en not_active Ceased
- 2021-09-23 MX MX2023003365A patent/MX2023003365A/es unknown
- 2021-09-23 KR KR1020237013253A patent/KR20230074515A/ko not_active Withdrawn
- 2021-09-23 US US17/483,100 patent/US20220090012A1/en not_active Abandoned
- 2021-09-23 AU AU2021347907A patent/AU2021347907A1/en active Pending
- 2021-10-04 US US17/493,271 patent/US11679131B2/en active Active
- 2021-10-04 US US17/493,280 patent/US11497773B2/en active Active
- 2021-10-04 US US17/493,253 patent/US11679130B2/en active Active
-
2022
- 2022-11-10 US US18/054,521 patent/US11857574B2/en active Active
-
2025
- 2025-02-18 US US19/056,007 patent/US20250179146A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022064428A5 (https=) | ||
| JP2023129663A (ja) | 改変ｔ細胞ならびにそれを作製および使用する方法 | |
| CA3133333A1 (en) | Chimeric receptors and methods of use thereof | |
| JP2021522820A5 (https=) | ||
| KR102588292B1 (ko) | 항-bcma 키메라 항원 수용체 | |
| JP2019525771A5 (https=) | ||
| CN113614108A (zh) | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 | |
| KR102823878B1 (ko) | 키메라 Notch 수용체의 면역원성을 감소시키는 방법 및 조성물 | |
| AU2020315796A1 (en) | Fusion polypeptide for immunotherapy | |
| KR20190133017A (ko) | 개선된 항원 결합 수용체 구성 | |
| IL264144B2 (en) | Antibody 18A2 against CLAUDIN and its use | |
| JP2019193652A (ja) | 前立腺特異幹細胞抗原に対する抗体およびその使用 | |
| KR20210089707A (ko) | 항-liv1 면역세포 암 치료법 | |
| KR20210092236A (ko) | 항-ptk7 면역세포 암 치료법 | |
| CN118510801A (zh) | 用于多发性骨髓瘤的靶向bcma的car-t细胞疗法 | |
| JP2020501512A5 (https=) | ||
| US20220185882A1 (en) | Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same | |
| Koch et al. | Recombinant antibodies to arm cytotoxic lymphocytes in cancer immunotherapy | |
| WO2020172641A1 (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same | |
| WO2023230471A2 (en) | Methods and compositions for immune cell crispr screens | |
| CA3217614A1 (en) | Chimeric receptors and methods of use thereof | |
| JPWO2020095107A5 (https=) | ||
| JPWO2022081516A5 (https=) | ||
| TW202309294A (zh) | 病毒載體生產系統 | |
| TW202242117A (zh) | 包含多順反子表現卡匣之重組載體及其使用方法 |